Loading
Muscle Physiology and Disorders / Adipokines, Inflammation, and Metabolic Diseases · Review
Frontiers in Oncology · August 11, 2026
Raises a question worth testing. It does not answer one.
This narrative review proposes that exercise-induced myokines (IL-15, Irisin, SPARC, FGF21) may counteract obesity-driven pro-tumorigenic signaling in gynecological cancers through multiple mechanistic pathways including NK cell recruitment, PI3K/Akt/mTOR inhibition, and metabolic reprogramming. The evidence base is mechanistic and preclinical rather than clinical; the review identifies a plausible biological hypothesis but does not demonstrate that myokine-based exercise interventions improve patient outcomes.
Narrative review. Obesity-driven gynecological malignancies, particularly endometrial carcinoma and specific ovarian cancer subtypes; review scope includes preclinical, mechanistic, and observational literature.. Intervention: Exercise-induced secretion of myokines (IL-15, Irisin/FNDC5, SPARC, FGF21). Compared with: Obesity-associated adipokine dysregulation, chronic low-grade inflammation, and hyperinsulinemia in sedentary state.
Obesity impairs skeletal muscle secretory profile, creating a tumor-permissive microenvironment in gynecological cancers IL-15 enhances anti-tumor immune surveillance by promoting Natural Killer cell recruitment and cytotoxic activity Irisin and SPARC inhibit cell proliferation and epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway modulation
No primary clinical trial data or hard patient outcomes (recurrence, mortality) reported
This review does not yet provide a basis for changing clinical practice. Clinicians should recognize the emerging mechanistic rationale for exercise in gynecological cancer prevention and treatment, but await prospective trials demonstrating that myokine-targeted or precision exercise interventions improve clinical outcomes.
This narrative review synthesizes mechanistic evidence from disparate preclinical and observational studies to propose a theoretical framework linking exercise-induced myokines to tumor suppression in obesity-driven gynecological cancers, but does not report primary clinical trial data or direct human outcome evidence.
As stated by the source record.
This review does not yet provide a basis for changing clinical practice. Clinicians should recognize the emerging mechanistic rationale for exercise in gynecological cancer prevention and treatment, but await prospective trials demonstrating that myokine-targeted or precision exercise interventions improve clinical outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity represents a cornerstone risk factor for gynecological malignancies, particularly endometrial carcinoma and specific ovarian cancer subtypes. This association is driven by a systemic milieu of chronic low-grade inflammation, adipokine dysregulation, and hyperinsulinemia. Conversely, skeletal muscle is now recognized as a dynamic endocrine organ that, through contraction-induced secretion of myokines, orchestrates a “muscle–tumor axis” capable of antagonizing pro-tumorigenic signaling. This narrative review aims to synthesize current evidence regarding the role of exercise-induced myokines in obesity-driven gynecological cancers, elucidating the mechanisms through which these molecules reshape the systemic and tumor microenvironment. A comprehensive search of PubMed/MEDLINE, Scopus, and Web of Science was conducted up to early 2026, focusing on myokine signaling, exercise physiology, and gynecological oncology. Chronic obesity significantly impairs the skeletal muscle secretory profile, fostering an environment conducive to tumor progression. Exercise-induced secretion of key myokines, specifically IL-15, Irisin (FNDC5), SPARC, and FGF21, counteracts these effects through multiple mechanisms. Irisin and SPARC directly inhibit cell proliferation and epithelial-mesenchymal transition (EMT) by modulating the PI3K/Akt/mTOR pathway. IL-15 enhances anti-tumor immune surveillance by promoting the recruitment and cytotoxic activity of Natural Killer (NK) cells. Furthermore, FGF21 and Irisin facilitate metabolic reprogramming by inducing adipose tissue browning and restoring the insulin/IGF-1 axis homeostasis. Myokines may serve as critical biological mediators linking physical activity to cancer protection. Understanding these exercise-induced molecular transducers may provide a robust rationale for developing “precision exercise” protocols as a tailored non-pharmacological strategy to improve oncological outcomes in gynecological cancer patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.